| FAP | Familial Amyloid Polyneuropathy |
|---|---|
| GBS | 1) Guillain-Barr Syndrome = PIP; Post-Infectious Polyneuropat... |
| ACIP | acute canine idiopathic polyneuropathy; Advisory Committee on Immunization Practices [CDC] |
| AIDP | acute idiopathic demyelinating polyneuropathy |
| CPN | central parenteral nutrition; chronic polyneuropathy; chronic pyelonephritis |
| nitrofurantoin polyneuropathy | <neurology> An axon loss polyneuropathy, often severe, seen in some patients treated with nitrofurantoin, particularly patients with chronic renal failure. (05 Mar 2000) |
|---|---|
| nutritional polyneuropathy | A disorder of multiple peripheral nerves, noted in beriberi, chronic alcoholism, and other clinical states, resulting from thiamin deficiency. (05 Mar 2000) |
| demyelinating polyneuropathy | A type of polyneuropathy in which almost solely the peripheral nerve myelin is affected; can be both familial (e.g., Charcot-Marie Tooth disease, type 1), or acquired (e.g., Guillain-Barre syndrome); on motor nerve conduction studies, manifested as conduction slowing or block. Synonym: segmental demyelinating polyneuropathy. (05 Mar 2000) |
| diabetic polyneuropathy | A distal, symmetrical, generally sensorimotor polyneuropathy that is a frequent complication of diabetes mellitus. (05 Mar 2000) |
| isoniazid polyneuropathy | An axonal loss polyneuropathy seen in some patients treated with isoniazid. (05 Mar 2000) |
| uraemic polyneuropathy | A distal sensory and motor polyneuropathy without conspicuous inflammation and ascribed to the metabolic effects of chronic renal failure. (05 Mar 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |
| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| non-steroidal anti-inflammatory drug | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |